Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 2/20 | 0.47 |
| ▸ | PRKCI | P41743 | 2/20 | 0.47 |
| ▸ | JAK1 | P23458 | 5/20 | 0.46 |
| ▸ | JAK2 | O60674 | 4/20 | 0.46 |
| ▸ | TYK2 | P29597 | 3/20 | 0.46 |
| ▸ | CCNK | O75909 | 1/20 | 0.40 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 3/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.37 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.37 |
| ▸ | RHEB | Q15382 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 2/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | CHUK | O15111 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9938223 | 0.83 | AXL (0.47) | AXLPRKCIJAK1JAK2TYK2 | |
| SCHEMBL31347303 | 0.83 | AXL (0.47) | AXLPRKCIJAK1JAK2TYK2 | |
| SCHEMBL17371702 | 0.80 | NUDT1 (0.43) | AXLPRKCIJAK1JAK2TYK2 | |
| SCHEMBL31177935 | 0.80 | NUDT1 (0.43) | AXLPRKCIJAK1JAK2TYK2 | |
| SCHEMBL1536840 | 0.78 | JAK3 (0.53) | AXLPRKCIJAK1JAK2TYK2 | |
| SCHEMBL1536982 | 0.77 | JAK3 (0.59) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL29588316 | 0.77 | AXL (0.56) | AXLPRKCIJAK1JAK2TYK2 | |
| SCHEMBL1154022 | 0.77 | AXL (0.56) | AXLPRKCIJAK1JAK2TYK2 | |
| SCHEMBL17681725 | 0.76 | AXL (0.44) | AXLPRKCIJAK1JAK2TYK2 | |
| SCHEMBL21818978 | 0.76 | ASPH (0.43) | AXLPRKCIJAK1JAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441735-B2 | Nitrogen-containing heterocyclic compound having NRF2 activation effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-10-14 | — | — | US | disclosed |
| US-20250171457-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-05-29 | — | — | US | disclosed |
| US-20250084093-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-03-13 | — | — | US | disclosed |
| EP-4446312-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-10-16 | — | — | EP | disclosed |
| CN-118488944-A | Nitrogen-containing heterocyclic compound having Nrf2 activation | 中外制药株式会社 | 2024-08-13 | — | — | CN | disclosed |
| WO-2023132369-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | 中外製薬株式会社 | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441735-B2 | Nitrogen-containing heterocyclic compound having NRF2 activation effect | KEAP1, NFE2L2, BACH1 | AXL 1973/4885PRKCI 3514/4885JAK1 2442/4885 |
| US-20250171457-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | KEAP1, NFE2L2, BACH1 | AXL 1973/4885PRKCI 3514/4885JAK1 2442/4885 |
| US-20250084093-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | KEAP1, NFE2L2, BACH1 | AXL 2141/4885PRKCI 3384/4885JAK1 2508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.